Clinical Trials Logo

Primary Immunodeficiency Disease clinical trials

View clinical trials related to Primary Immunodeficiency Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04842643 Completed - Clinical trials for Primary Immunodeficiency Disease

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Start date: April 27, 2021
Phase: Phase 3
Study type: Interventional

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study. The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

NCT ID: NCT03961009 Completed - Clinical trials for Primary Immunodeficiency Disease

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

CARES10
Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

NCT ID: NCT02810444 Completed - Clinical trials for Primary Immunodeficiency Disease

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Start date: October 4, 2016
Phase: Phase 3
Study type: Interventional

This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)

NCT ID: NCT02627300 Completed - Clinical trials for Primary Immunodeficiency Disease

Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial

Start date: March 2016
Phase: Phase 3
Study type: Interventional

Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2.5 years is reached (whichever occurs first).